Clinigen teams up with Horizon on RAVICTI
29th Jun 2016 12:20
(ShareCast News) - Clinigen Group was celebrating on Wednesday, as its Idis Managed Access division and Nasdaq-traded Horizon Pharma initiated a Managed Access Programme in Europe for Horizon's RAVICTI oral liquid. The AIM-traded firm said RAVICTI received centralised marketing approval from the Eur
Read moreClinigen Group's acquisitions boost first half growth
19th Jan 2016 09:23
(ShareCast News) - Clinigen Group says it has had a solid first half performance, driven by acquisitions and organic growth. The AIM-listed company issued a trading update for the six months to 31 December on Tuesday. It said revenue had risen 116% and it had doubled its gross profit from last year
Read moreClinigen directors cash in options
7th Oct 2015 16:57
(ShareCast News) - Clinigen Group directors have taken home a nice mid-week bonus after three exercised their options and a fourth sold a large portion of his stake. Chief executive Peter George, deputy chief executive Shaun Chilton and chairman Peter Allen all exercised their options which were pro
Read moreClinigen to acquire Link and strengthen global footprint
22nd Sep 2015 12:17
(ShareCast News) - Clinigen Group has announced a proposed acquisition of Link Healthcare. The purchase, announced on Tuesday, would strengthen the pharmaceuticals company's global footprint in Asia, Africa and Australasia. Clinigen chief executive Peter George said Link had excellent local knowled
Read moreClinigen Group strikes alliance to expand in US
17th Sep 2015 09:24
(ShareCast News) - UK-based pharmaceuticals company Clinigen Group and US-based Cumberland Pharmaceuticals have struck a strategic alliance to expand each company's global reach. The deal will build on Clinigen's existing US relationships by providing support from Cumberland in the development, m
Read moreClinigen completes £225m Idis takeover
24th Apr 2015 15:10
Pharmaceutical group Clinigen has completed the takeover of sector peer Idis for £225m. The AIM-listed group said the deal will boost its access to unlicensed drugs for cancer treatment and other disease in over 120 different countries. In a statement released on Friday, Clinigen said the medicines
Read moreThursday broker round-up UPDATE
25th Sep 2014 08:48
Amec: UBS raises target price from 1100p to 1215p upgrading from neutral to buy. Aquarius Platinum: Citi lowers target price from 26p to 22p maintaining a neutral rating. Arrow Global: Panmure Gordon ups target price from 335p to 360p and keeps a buy recommendation. Barr (AG): Numis ups target pri
Read moreTuesday broker round-up
26th Aug 2014 10:16
Bioquell: N+1 Singer upgrades from hold to buy with an unchanged target price of 112p. Investec cuts target price from 133p to 98p, while upgrading from hold to add. Circle Oil: Investec moves target price from 50p to 70p and maintains a buy recommendation. Clinigen Group: N+1 Singer ups target pr
Read moreWednesday broker round-up UPDATE
20th Aug 2014 10:50
BHP Billiton: Deutsche Bank raises target price from 1450p to 1500p and leaves its buy recommendation unchanged. Investec increases target price from 2175p to 2205p and maintains a hold recommendation. Big Yellow Group: Liberum Capital ups target price from 565p to 591p and keeps its buy recommenda
Read moreClinigen Group acquires oncology drug from AstraZeneca
20th Aug 2014 09:37
Pharmaceutical group Clinigen has acquired the global rights to Astrazeneca's drug Ethyol, which is expected to treat dry mouth in patients receiving radiation treatment. The drug, which was purchased for an undisclosed amount, will be the group's fifth product in its specialty pharmaceuticals port
Read moreThursday broker round-up UPDATE
24th Jul 2014 08:59
Afren: JP Morgan shifts target price from 180p to 188p upgrading from underweight to overweight. Anglo American: Jefferies raises target price from 1550p to 1700p and reiterates a hold recommendation. Antofagasta: Jefferies increases target price from 825p to 1000p upgrading from hold to buy. ARM
Read moreBroker tips: Weir, Rio Tinto, Polymetal, Clinigen
7th Jul 2014 12:39
Shares in Weir Group were making decent gains on Monday morning after the stock was upgraded from 'neutral' to 'buy' at Citigroup, which said that the engineer's opportunities in oil and gas are "underappreciated" by the market. The bank said that "Weir deserves a premium rating to the sector to re
Read moreInvestec upgrades Clinigen to 'buy' after recent sell-off
7th Jul 2014 12:29
Investec has upgraded pharmaceutical group Clinigen from 'hold' to 'buy', saying that even on a lower target price "we think the shares offer an attractive opportunity". "Clinigen's stock has fallen circa 40% since its interim results in March, when numbers were in line but growth was no longer as
Read moreClinigen Group agrees new credit facility with RBS
4th Apr 2014 07:47
Pharmaceutical company Clinigen Group has agreed a new four-year 35m pound multi-currency revolving credit facility with Royal Bank of Scotland (RBS). Under the agreement, Clinigen can request an additional £15m on the same terms. The facility replaces the existing £20m facility with RBS and is sec
Read moreMonday broker round-up UPDATE
31st Mar 2014 10:41
African Minerals: Credit Suisse cuts target price from 280p to 200p maintaining a neutral rating. Anglo American: Credit Suisse reduces target price from 1900p to 1800p and retains an outperform rating. ARM Holdings: Barclays takes target price from 1125p to 1200p and reiterates an overweight reco
Read more